{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:31:45Z","timestamp":1784752305581,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejca.2017.12.022","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T04:01:31Z","timestamp":1517630491000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Germline BAP1 -positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy"],"prefix":"10.1016","volume":"92","author":[{"given":"Phoebe","family":"Star","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Max","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Guitera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2017.12.022_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cge.12501","article-title":"A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma","volume":"88","author":"Wadt","year":"2015","journal-title":"Clin Genet"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.022_bib2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.022_bib3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ejca.2017.12.022_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.ejca.2017.12.022_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/gcc.22129","article-title":"Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases","volume":"53","author":"Pilarski","year":"2014","journal-title":"Gene Chromosome Canc"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.022_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.ejca.2017.12.022_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.022_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.08.038","article-title":"Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome","volume":"74","author":"Soura","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2017.12.022_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","article-title":"Tumours associated with BAP1 mutations","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.022_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","article-title":"Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature","volume":"153","author":"Haugh","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2017.12.022_bib11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","article-title":"Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations","volume":"133","author":"Gupta","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.022_bib12","doi-asserted-by":"crossref","first-page":"e35295","DOI":"10.1371\/journal.pone.0035295","article-title":"Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families","volume":"7","author":"Njauw","year":"2012","journal-title":"PLos One"},{"issue":"2","key":"10.1016\/j.ejca.2017.12.022_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1017\/thg.2015.12","article-title":"Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases","volume":"18","author":"Aoude","year":"2015","journal-title":"Twin Res Human Genet: Off J Int Soc Twin Studies"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.022_bib14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.ejca.2017.12.022_bib15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.022_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/CMO.S15239","article-title":"The importance of multidisciplinary Approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment","volume":"8","author":"Battaglia","year":"2014","journal-title":"Clin Med Insights Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.12.022_bib17","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thoracic Oncol: Off Pub Int Associ Study of Lung Canc"},{"key":"10.1016\/j.ejca.2017.12.022_bib18","series-title":"NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Stage 2 Consultation","author":"NHMRC","year":"2009"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.022_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/PAT.0b013e3283653818","article-title":"BAP1 expression in cutaneous melanoma: a pilot study","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"issue":"7","key":"10.1016\/j.ejca.2017.12.022_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejca.2017.12.022_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2017.12.022_bib22","unstructured":"Institute ADR. Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma Australia2013 [21\/7\/2017]. Available from: http:\/\/asbestosresearch.org.au\/files\/Guidelines_for_the_diagnosis_and_treatment_of_malignant_pleural_mesothelioma.pdf."},{"issue":"2","key":"10.1016\/j.ejca.2017.12.022_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2478\/v10019-010-0027-7","article-title":"3T MRI in evaluation of asbestos-related thoracic diseases \u2013 preliminary results","volume":"44","author":"Podobnik","year":"2010","journal-title":"Radiol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.12.022_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00261-014-0224-8","article-title":"Multimodality imaging of common and uncommon peritoneal diseases: a review for radiologists","volume":"40","author":"Vicens","year":"2015","journal-title":"Abdom Imag"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.022_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00261-016-0743-6","article-title":"Inherited renal carcinomas","volume":"41","author":"Kawashima","year":"2016","journal-title":"Abdom Radiol (New York)"},{"key":"10.1016\/j.ejca.2017.12.022_bib26","unstructured":"WHO. Screening for various cancers Switzerland: World Health Organization; [2\/7\/2017]. Available from: http:\/\/www.who.int\/cancer\/detection\/variouscancer\/en\/."},{"issue":"6","key":"10.1016\/j.ejca.2017.12.022_bib27","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bjd.14035","article-title":"Cross-sectional analysis of the dermoscopic patterns and structures of melanocytic naevi on the back and legs of adolescents","volume":"173","author":"Fonseca","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.ejca.2017.12.022_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"Gene of the month: BAP1","volume":"69","author":"Wang","year":"2016","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.022_bib29","first-page":"717","article-title":"A population-based analysis of germline BAP1 mutations in melanoma","volume":"26","author":"O'Shea","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.ejca.2017.12.022_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Canc Res MCR"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917315113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917315113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T06:56:52Z","timestamp":1535093812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917315113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":30,"alternative-id":["S0959804917315113"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}